BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 940.61M | 885.72M | 874.84M | 599.82M | 557.51M |
| Total Other Revenue | -- | -- | 11.29M | 18.64M | 19.41M |
| Total Revenue | 940.61M | 885.72M | 874.84M | 599.82M | 557.51M |
| Cost of Revenue | 216.64M | 207.02M | 183.16M | 189.15M | 186.65M |
| Gross Profit | 723.97M | 678.70M | 691.68M | 410.67M | 370.86M |
| SG&A Expenses | 333.05M | 356.46M | 344.37M | 333.31M | 315.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 549.70M | 563.48M | 527.53M | 522.46M | 502.05M |
| Operating Income | 390.92M | 322.24M | 347.30M | 77.36M | 55.46M |
| Income Before Tax | -381.19M | -454.18M | 267.39M | -6.62M | -32.19M |
| Income Tax Expenses | 3.49M | 3.81M | 3.53M | 2.16M | 3.52M |
| Earnings from Continuing Operations | -384.67 | -457.98 | 263.86 | -8.78 | -35.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -384.67M | -457.98M | 263.86M | -8.78M | -35.71M |
| EBIT | 390.92M | 322.24M | 347.30M | 77.36M | 55.46M |
| EBITDA | 395.32M | 326.46M | 350.79M | 80.79M | 58.51M |
| EPS Basic | -1.44 | -1.73 | 1.25 | -0.04 | -0.17 |
| Normalized Basic EPS | 0.95 | 0.79 | 0.85 | 0.00 | -0.08 |
| EPS Diluted | -1.49 | -1.77 | 1.21 | -0.05 | -0.18 |
| Normalized Diluted EPS | 0.91 | 0.76 | 0.82 | 0.00 | -0.08 |
| Average Basic Shares Outstanding | 917.88M | 872.92M | 839.55M | 835.96M | 832.69M |
| Average Diluted Shares Outstanding | 946.57M | 901.29M | 874.30M | 862.41M | 849.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |